|
|
|
By Drug Delivery Leader: Sit And Deliver | Fundamental goals of immuno-oncology therapies are to generate T-cell responses and overcome immunosuppression. In this episode of Sit and Deliver, host Tom von Gunden talks with Syncromune CEO Eamonn Hobbs about using injection- and infusion-based drug-device combination therapies in targeting solid tumor cancers. | |
|
|
Design Controls For Delivery Devices, Part 2: Practical Tips | By Fran DeGrazio, executive editor, Drug Delivery Leader | Here, the author provides recommendations for implementing Design Controls in the development of combination products and other drug delivery devices. In outlining tips for drug-device product developers, DeGrazio focuses on key considerations, including risk management, chemical and functional compatibility, and regulatory compliance. |
|
|
|
|
| Elastomer Formulations And Vial Containment Performance | Article | By T. Page McAndrew, Ph.D. and Victoria Morgan, West Pharmaceutical Services, Inc. | Examine the results of two, two-year studies that indicate good container closure integrity performance that can be achieved with stoppers of a given elastomer, independent of configuration. |
|
|
|
| Nanoparticle Formulations For Patient-Centric Dosing | Webinar | Nanoform | Explore how bioavailability of poorly soluble APIs can be improved and patient compliance enhanced by reducing the size or number of tablets that a patient must take to achieve the required dose. |
|
|
|
|
|
.png){kind=logo}
